Acadian Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Acadian Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Buy	5,848 +3,421	+141%	+$742K	﹤0.01%	1161
2026 Q1	$410K	Buy	2,427 +1,709	+238%	+$295K	﹤0.01%	1410
2025 Q4	$131K	Buy	+718	New	+$100K	﹤0.01%	1617
2024 Q4	–	Sell	-2,408	Closed	-$216K	–	1651
2024 Q3	$216K	Buy	+2,408	New	+$210K	﹤0.01%	1336
2016 Q3	–	Sell	-1,909	Closed	-$14K	–	1412
2016 Q2	$14K	Buy	+1,909	New	+$17.6K	﹤0.01%	1163

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management's AXSM Position: Q2 2026 in Review

Acadian Asset Management increased its Axsome Therapeutics (AXSM) stake by 141% in Q2 2026, buying an estimated $742K and bringing the position to 5,848 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1161.

Acadian Asset Management first reported a position in AXSM in Q2 2016 and has held it in 5 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Acadian Asset Management held 5,848 shares of Axsome Therapeutics worth $1.43M as of Q2 2026.
Acadian Asset Management bought 3,421 Axsome Therapeutics shares in Q2 2026, an estimated $742K.
Axsome Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1161 holding.
Acadian Asset Management first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 5 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.